



Atara Biotherapeutics  
 Investor Relations Department  
 701 Gateway Blvd, Suite 200  
 South San Francisco, CA 94080  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

#### NASDAQ: ATRA

Last Trade:	14.65
Trade Time:	4:00 PM ET Nov 20, 2017
Change:	0.05 <span style="color: green;">↑</span> (+0.342%)
Day Range	14.15 - 14.80
52-Week Range	11.80 - 23.00
Volume	97,824


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Atara Biotherapeutics is a leading "Off-the-Shelf" T-cell immunotherapy company developing products for patients with cancer and Multiple Sclerosis (MS). The company was founded in 2012, and since 2014 the company's stock has been publicly traded on Nasdaq under the symbol ATRA.

Atara's most advanced product candidate, ATA129, for cancer patients with rituximab refractory Epstein-Barr virus (EBV) associated Post-Transplant Lymphoproliferative Disease (EBV-... [\(more\)](#))

## Stock Performance



### Press Releases [\[ View all \]](#)

- Nov 9, 2017  
[Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights](#)
- Nov 7, 2017  
[Atara Biotherapeutics to Participate in Four Upcoming Investor Conferences](#)
- Nov 1, 2017  
[Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus \(EBV\)-Associated Cancers](#)
- Oct 26, 2017  
[Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus \(CMV\) Infection](#)

### Upcoming Events [\[ View all \]](#)

- Nov 29, 2017 4:35 PM ET  
[Evercore ISI BioPharma Catalyst/Deep Dive Conference](#)
- Dec 5, 2017  
[Global Mizuho Investor Conference NY](#)
- Financials [\[ View all \]](#)**
- [Third Quarter Financial Results](#)
- Mar 9, 2017  
[Annual Report \(10-K\)](#)
- Apr 25, 2017  
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017  
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017  
[Quarterly Report \(10-Q\)](#)